QLIDA Diagnostics develops next-generation biomarker diagnostic tests.

QLIDA develops next-generation biomarker diagnostic tests. The company’s proprietary portable, hand-held platform can be used for diagnosis of life-threatening diseases such as cancer and cardiovascular disease, through the use of a nanotechnology-based protein detection.

QLIDA has been collaborating with Drexel University to develop its proprietary test, Quantum-dot Linked Immuno-Detection Assay (QLIDA), to create a quantitative biomarker detection platform, enabling early detection of proteins associated with disease. The company is currently developing an ultrasensitive test for cardiovascular disease to be used in point of care testing.

Sector: Healthcare
Sub Sector: Medical Devices
Industry: Healthcare
Status: Active
County: Philadelphia

Contact Information


Michael Boyce-Jacino



VP of Engineering

Michael Kochersperger